Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

VICT3R · Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research

HORIZONStatus: SIGNED1 September 202429 February 2028EU funding €13,524,750Call HORIZON-JU-IHI-2023-05

VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of animals used in experimental studies performed during the nonclinical drug and chemical safety evaluation by replacing the animals of the concurrent controls groups (CCGs) with Virtual Control Groups (VCGs). These VCGs will be generated by means of state-of-the-art statistical or artificial intelligence (AI) approaches that optimally exploit the wealth of historical data from control animals accumulated over decades by pharmaceutical companies and other relevant industrial and academic sectors. The VCG concept was conceived and prototyped during the recently finished eTRANSAFE IMI2 project for its application in the nonclinical safety assessment of the pharmaceutical industry. A preliminary evaluation of the VCG concept carried out in the eTRANSAFE project demonstrated that it is generally feasible, yet scientifically and operationally challenging and must therefore be refined before its adoption for regulatory hazard and risk assessment. The main challenges consist of adequate data collection and curation, identification of key variables to achieve optimal matching between VCGs and CCGs, and validation of procedures including compliance with Good Laboratory Practice (GLP). These challenges will be systematically tackled in VICT3R for achieving the full development and regulatory acceptance of the VCG concept. VICT3R will collect, curate and analyse large data sets of control animals from different species to produce a large high-quality database. The database will be made available to VICT3R partners, regulators, and policy makers with the purpose to allow maturation of the VCG concept and to prove its validity, reproducibility and robustness. While VICT3R will be primarily focused on repeated dose toxicity studies, the extension of the VCG concept to other types of studies involving animals will also be tackled. VICT3R will promote that its database and software platform is maintained and expanded long term.

Consortium · 45 organisations

coordinator

UNIVERSIDAD POMPEU FABRA

ES · €2,552,250

associatedPartner

MERCK LIFE SCIENCE KGAA

DE

participant

PHUSE CUIDEACHTA FAOI THEORAINN RATHAIOCHTA

IE · €621,500

participant

AMGEN RESEARCH (MUNICH) GMBH

DE

participant

ASTRAZENECA UK LIMITED

UK

participant

ABBVIE INC

US

participant

SANOFI-AVENTIS DEUTSCHLAND GMBH

DE

participant

GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

UK

participant

TAKEDA PHARMACEUTICALS INTERNATIONAL AG

CH

participant

UCB BIOPHARMA

BE

associatedPartner

Janssen Research & Development, LLC

US

associatedPartner

MERCK ELECTRONICS KGAA

DE

participant

SYNCWORK AKTIENGESELLSCHAFT

DE · €835,000

participant

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV

DE · €1,457,125

participant

NOVARTIS PHARMA AG

CH

participant

VRIJE UNIVERSITEIT BRUSSEL

BE · €639,750

participant

IPSEN INNOVATION SAS

FR

participant

F. HOFFMANN-LA ROCHE AG

CH

participant

MEDBIOINFORMATICS SOLUTIONS SL

ES · €686,250

participant

ORION OYJ

FI

associatedPartner

BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

DE

associatedPartner

Incyte Corporation

US

participant

MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN

DE

associatedPartner

Istituto di Ricerche Biomediche Antoine Marxer RBM S.p.A.

IT

participant

TECHNISCHE UNIVERSITAT DORTMUND

DE · €456,125

participant

BASF SE

DE

participant

BOEHRINGER INGELHEIM INTERNATIONALGMBH

DE

participant

GRITSYSTEMS AS

DK · €1,813,250

participant

ORGANON SRL

RO · €751,875

associatedPartner

JANSSEN VACCINES & PREVENTION BV

NL

participant

INSTEM SCIENTIFIC LIMITED

UK

participant

INSTITUT SERVIER DE MEDECINE TRANSLATIONNELLE

FR

participant

UNIVERSITAT KONSTANZ

DE · €248,750

participant

PFIZER INC

US

participant

ZOETIS BELGIUM SA

BE

participant

BAYER AKTIENGESELLSCHAFT

DE

participant

NOVO NORDISK A/S

DK

participant

DECIPHEX LIMITED

IE · €1,211,250

participant

SYNAPSE RESEARCH MANAGEMENT PARTNERS SL

ES · €940,625

participant

CAATevents gGmbH

DE · €376,250

participant

BARCELONA SUPERCOMPUTING CENTER CENTRO NACIONAL DE SUPERCOMPUTACION

ES · €934,750

participant

BRISTOL-MYERS SQUIBB COMPANY CORP

US

participant

JANSSEN PHARMACEUTICA NV

BE

participant

INCYTE BIOSCIENCES DISTRIBUTION B.V

NL

associatedPartner

MERCK HEALTHCARE KGAA

DE

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.